Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
6.64
+0.94 (16.49%)
Oct 21, 2025, 3:03 PM EDT - Market open
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M AUD with 538.86% growth. Radiopharm Theranostics had revenue of 10.07M in the half year ending June 30, 2025, with 417.19% growth.
Revenue (ttm)
12.51M AUD
Revenue Growth
+538.86%
P/S Ratio
5.07
Revenue / Employee
893,727 AUD
Employees
14
Market Cap
41.60M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |